Conditions: Glioblastoma Multiforme
Keywords: GBM Malignant gliomas
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 222
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.

Detailed description:

Arms:
arm 1: cabozantinib, 175 mg, taken orally once per day (qd). arm 2: cabozantinib, 125 mg, taken orally once per day (qd). arm 3: cabozantinib, 125 mg, taken orally once per day (qd).

Interventions: intervention 1: XL184
Intervention descriptions: intervention 1: Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing

Protocol document: